Story
Insmed Stock Soars on Blockbuster Brinsupri Sales and Raised Forecast

Shares of Insmed (INSM) surged more than 19% in pre-market trading after the biopharmaceutical company announced second-quarter 2026 financial results that decisively beat Wall Street estimates and raised its full-year guidance, alleviating prior investor concerns about its growth trajectory.
Blockbuster Quarter Exceeds Forecasts
Insmed reported a dramatic year-over-year revenue increase of approximately 265%, driven by the strong commercial launch of its drug Brinsupri. The quarterly performance significantly surpassed analyst expectations on both the top and bottom lines.
- Total Revenue: $425.5 million, compared to consensus estimates of approximately $392.5 million.
- Brinsupri Revenue: $309.2 million, well above the forecasted range of $285 million to $300 million.
- Net Loss Per Share: $0.06, a stark improvement from a loss of $1.70 in the same period a year ago and substantially better than the anticipated loss of around $0.70 per share.
Management Upgrades Full-Year Guidance
Addressing a key point of concern from the previous quarter, management issued a significant upgrade to its financial outlook. The company raised its full-year 2026 revenue guidance for Brinsupri to a range of $1.25 billion to $1.40 billion, up from its prior forecast of at least $1 billion.
AdInsmed also increased its long-term peak revenue estimates for its key products, projecting Brinsupri could generate more than $7 billion and its pipeline candidate TPIP could exceed $6 billion. CEO Will Lewis stated in the release that the U.S. launch of Brinsupri "continues to be met with significant enthusiasm and demand from patients and physicians."
Market Context and Investor Sentiment
The strong market reaction reflects a reset in investor sentiment. Following its first-quarter report, Insmed's stock had fallen over 20% despite beating estimates, as investors were disappointed by rising expenses and the lack of a guidance increase. That selloff left the stock trading near its 52-week low.
Today's combination of a substantial earnings beat, a near-breakeven quarter, and a robust outlook for Brinsupri appears to have restored confidence in the drug's commercial momentum. The stock's sharp upward move came in a largely flat market, with the S&P 500 trading up just 0.15%, underscoring the company-specific nature of the news.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.